Pluristem Therapeutics PSTI now has CASH, Institutional support & a major analyst (Jefferies). With today's markets, now is the time to already have your funding. Regardless of the stock price, they should be able to finish this year with at least one phase 3 study finished. PSTI should also have COVID phase II trials completed addressing the most critical and urgent need for COVID-19 SARS CoV-2 patients that are admitted into the ICU.
For those sleuths studying COVID stemcell treatments from others such as Mesoblast (MESO) , Miami Hospital (that also got compassionate use using similar approach with MSC stem cells), ATHX and Celularity, then collectively statics start looking impressive for MSC stem cells for treating COVID19 with severe symptoms even for such a small scale sample. The amazing fact is that compassionate use is used only in the most dire ICU cases. Look at improvement in organ function as another benefit. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new bonus market potential. Competitors are spreading a lot of misinformation in “articles”, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta and the consistency of their whole process. Many do not know that years ago Pluristem had promising pre-clinical results treating ARDS but at the time had to put it on the back burner using their limited funds to further their current clinical trials.
Pluristem is the only really pure play as other top competitors either pay royalties or license fees, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as this virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that and it can also work with other treatments as well.
Why invest in PSTI & not one of the other competitors?
1) Market Cap opportunity. Valued at less than half the Market Cap of the nearest competitor means that $PSTI would have to double in stock price just to be at an equal market value with $ATHX and 5x the current stock price to be valued the same as $MESO, so the opportunity for investors is significant just to catch up with competitive market valuation.
2) Ability to Scale. This is why Pluristem was chosen by the EU as the only company to get a low cost 50 million Euro loan because they had already been ramping up for large scale production before this pandemic.
3) They own the IP and they continue to update and improve the process for greater efficiency. As if the current patented 3D bioreactor that can make 20,000 doses from one placenta was not enough, they have a new patent for a modular 3D bioreactor for even higher production.
4) They have their own manufacturing. This gives them full control over the process for consistency and will keep the costs lower than the competition. Their patented advanced process can be used for many other plant and animal cell cultures in the future when time and capitol permit. This process alone might be worth more than their current MarketCap.
5) Off the shelf product. The cells can be used on anyone without matching. They have the full cold storage chain process all set up even to the point of their patented thawing device that insures consistency with the optimal potency. They can transport their cells to any hospital in about 4 hours.
6) They use placenta cells from a young healthy C-section birth. It has yet to be proven, but some theorize that these cells have additional beneficial properties that are not found in cord blood or bone marrow MSC stem cells (Celularity also uses placenta cells).
7) Intramuscular injections delivery. This allows the PLX cells to give active therapeutic benefits much longer than intravenous and does not interfere with any other medications that may be administered IV.
8) Accelerated clinical environment. People want solutions that are safe and non-toxic and they want them now. I don't know if one of the governments will pickup the acute radiation PLX-18 or if NASA will continue funding the space atrophy studies but once we get our CLI phase III results and approval, off-label can do many things in this new paradigm.
Disclaimer: Information is offered for discussion purposes only and is not guaranteed to be complete, unbiased, current or accurate and is subject to change without notice and is not be relied upon to make any investment decisions.
